Dendreon Corp fka DNDNQ

[Gift_Horse]

ANALYST SETS NEW TARGET PRICE AT ZERO!

I could see this coming, which is why I posted this some time ago:

WHY I SOLD DENDREON TO BUY SCANCELL

There is little doubt in my mind that the rise of Scancell spells the doom of Dendreon and other companies that rely on extracting patients' cells to make up their one patient at a time cancer vaccines. To be honest Dendreon's business model stinks and it can't possibly compete against re-programable DNA dendritic cell vaccines that Scancell is now producing.

Not only can Scancell treat unlimited numbers of patients from the same batch but their vaccines can be easily re-programmed to treat a different cancer simply by altering a tiny piece of code.

What Scancell does is to inject strands of DNA into dendritic cells at the skin's surface and this programs these cells to produce peptide mimics of cancer antigens. This leads to a far more intense Killer T Cell response against cancer than any known method and Scancell owns the patents.

Unlike Dendreon and Northwest Bio, Scancell can actually shrink tumors and unlike Celldex, Scancell can actually eliminate them as well. So not only is Scancell more than a match for other cancer vaccines but can also compete with today's monoclonal inhibitors and do so without toxicity!

Scancell is coming up for sale in the not too distant future and its board have already been talking to suitors. The CEO has promised investors they can expect "a very attractive multiple of current valuation." Speculation has fleshed this out with guesstimates between $5 and $18 per share. Either way its current price below $1 is an opportunity I wasn't going to walk away from.

Last year Scancell was the best performing stock in London and the world's best performing biotech. But its journey skyward has barely begun. Its all upside whereas Dendreon is all downside. That's why I pressed the button and made the switch!

David Nierengarten analyst at Wedbush Securities sums up his doom laden analysis of Dendreon's future